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Abstract: Aim: To gather and review data describing the epidemiology of schizophrenia and clinical guidelines  
for schizophrenia therapy in seven Central and Eastern European countries, with a focus on negative symptoms.  
Methods: A literature search was conducted which included publications from 1995 to 2012 that were indexed in key da-
tabases. Results: Reports of mean annual incidence of schizophrenia varied greatly, from 0.04 to 0.58 per 1,000 popula-
tion. Lifetime prevalence varied from 0.4% to 1.4%. One study reported that at least one negative symptom was present in 
57.6% of patients with schizophrenia and in 50–90% of individuals experiencing their first episode of schizophrenia. Pri-
mary negative symptoms were observed in 10–30% of patients. Mortality in patients with schizophrenia was greater than 
in the general population, with a standardized mortality ratio of 2.58–4.30. Reasons for higher risk of mortality in the 
schizophrenia population included increased suicide risk, effect of schizophrenia on lifestyle and environment, and pres-
ence of comorbidities. Clinical guidelines overall supported the use of second-generation antipsychotics in managing 
negative symptoms of schizophrenia, although improved therapeutic approaches are needed. Conclusion: Schizophrenia is 
one of the most common mental illnesses and poses a considerable burden on patients and healthcare resources alike. 
Negative symptoms are present in many patients and there is an unmet need to improve treatment offerings for negative 
symptoms beyond the use of second-generation antipsychotics and overall patient outcomes. 
Keywords: Epidemiology, guidelines, mortality, negative symptoms, pharmacotherapy, schizophrenia. 
INTRODUCTION 
Schizophrenia is a serious public health problem and is 
ranked among the most disabling diseases in the world [1]. It 
is broadly characterized by three domains of psychopa-
thology: positive symptoms (hallucinations, delusions), 
negative symptoms (social withdrawal, lack of motivation 
and emotional reactivity) and cognitive deficits (working 
memory, attention executive function) [2]. The worldwide 
prevalence of schizophrenia is estimated at approximately 
1% [3]. Schizophrenia is one of the most costly mental dis-
orders in terms of human suffering and societal expenditure 
[4]. 
At any point of time, negative symptoms affect up to 
60% of patients with schizophrenia [5], with 30% having 
primary negative symptoms that are sufficiently prominent 
to warrant clinical attention [6, 7]. Currently available  
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antipsychotics are not indicated for the treatment of negative 
symptoms; therefore, many patients experience persistent 
negative symptoms after their positive symptoms have been 
controlled [8]. Negative symptoms impact patients’ ability to 
live independently, to perform activities of daily living, to be 
socially active and maintain personal relationships, and to 
work or study [9]. In addition, the severity of negative symp-
toms is often a predictor of poor patient functioning [9, 10]. 
While a number of studies have characterized the epide-
miology of schizophrenia at a country-level, differences 
among countries, particularly regarding perceptions of the 
negative symptoms of schizophrenia, have not been explored 
in depth. Furthermore, understanding of local and interna-
tional treatment guidelines for the management of negative 
symptoms is lacking.  
OBJECTIVES 
A comprehensive literature review was undertaken to 
gather data on the epidemiology of schizophrenia and in par-
ticular, the negative symptoms of schizophrenia in seven 
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Central and Eastern European (CEE) countries: Croatia, Es-
tonia, Hungary, Poland, Serbia, Slovakia and Slovenia.  
This project is the first of its kind to characterize the epi-
demiology and treatment of schizophrenia in these CEE 
countries. An analysis in Western Europe has been described 
in several previous studies, including the European Schizo-
phrenia Cohort (EuroSC) study, with data from France, 
Germany and the UK (N=1208 patients) and the European 
multinational EPSILON study which was conducted in The 
Netherlands, Denmark, the UK, Spain and Italy (N=404 pa-
tients) [11-14]. These countries were selected because col-
lectively they may offer a new perspective from which to 
consider schizophrenia treatment and epidemiology.  
Search criteria included literature relating to epidemiol-
ogy, clinical guidelines and recommendations, current stan-
dards of care, costs of illness, resource utilization, health-
related quality of life, and stigmatization and discrimination 
related to schizophrenia. This manuscript will focus on epi-
demiological considerations and current clinical guidelines 
and recommendations for the treatment of negative symp-
toms. Additional results from this research, such as the qual-
ity of life findings, will be published separately.  
METHODS 
The literature review included publications from 1995 to 
2012 that are indexed in MEDLINE (via PubMed), the 
Cochrane Library (all libraries) and the UK Centre for Re-
views and Dissemination. The search strategy was developed 
using the term ‘schizophrenia’ and its synonyms were tar-
geted through specific filters to identify the following: 
• Publications from key countries: the country name was 
combined with the result of the schizophrenia synonyms 
search. 
• Relevant papers on the negative symptoms of schizo-
phrenia: a filter ‘negative symptoms’ and its synonyms 
was added. 
• Publications concerning schizophrenia epidemiology: a 
filter was applied using the terms ‘epidemiology’, ‘preva-
lence’ and ‘incidence’. 
• Publications concerning clinical practice, treatment op-
tions, and standard care: a filter on ‘antipsychotic drugs’ 
combined with ‘psychosocial therapy’ and ‘psychother-
apy’ and its synonyms according to MeSH terms was ap-
plied. 
Relevant websites, such as the National Guidelines 
Clearinghouse, National Institute for Health and Care Excel-
lence and European Medicines Agency, were also searched 
using the terms: ‘schizophrenia’ and ‘negative symptoms’ in 
order to identify guidelines and recommendations for drugs 
and treatments used in European countries for schizophrenia, 
and other relevant papers.  
Additionally, in each of the seven countries of interest, 
searches were performed to identify relevant local-language 
publications. Data sources included health technology as-
sessment agencies, patient registries, national medical jour-
nals, national health services, national/central statistical of-
fices, national psychiatric associations and local psychiatric 
websites. A search was also carried out for review articles, 
systematic reviews and primary research relating to guide-
lines and recommendations about schizophrenia treatment, 
costs and burden of disease, resource utilization, stigmatiza-
tion and discrimination related to schizophrenia. 
RESULTS 
Epidemiology of Schizophrenia and Negative Symptoms 
Altogether more than 9,000 records from three databases 
were screened in order to identify relevant studies that ful-
filled predefined inclusion criteria. For epidemiological data 
and guidelines, more than 1050 records were initially identi-
fied (including 650 records for country-specific data). This 
initial search was further refined by the defined filters to 
identify 14 publications on the epidemiology of schizophre-
nia [15-28]. 
The findings confirmed that schizophrenia is a common 
psychiatric disorder. The mean incidence of schizophrenia 
reported in the studies varied greatly from 0.04 to 0.58 per 
1,000 individuals in a population per year [16, 29], while 
lifetime prevalence ranged from 0.4% to 1.4% [15, 21]. This 
variance was explained mainly by differences in the diagnos-
tic criteria used in the studies. Several of the studies included 
were conducted in the period prior to the publication of stan-
dard diagnostic criteria, such as the DSM-IV and ICD-10; 
(published in 1994 and 1992, respectively). The actual 
prevalence of schizophrenia is likely to be higher than these 
figures if undertreated and never-treated cases are taken in to 
account [29]. 
Length of illness, which influences prevalence, is deter-
mined by several factors, such as life expectancy, excess 
mortality after disease onset and impact of treatment. The 
relatively high prevalence of schizophrenia is due to the 
early age of onset and the chronic recurring disease course. 
Gender differences in schizophrenia include an earlier age of 
onset in men, a more severe disease course, and a slightly 
higher prevalence, with a male to female ratio of 2:1 [15]. 
However, data relating to gender differences are inconsistent 
and only some of the study authors agreed that prevalence of 
schizophrenia is higher in males than in females, while oth-
ers described the ratio as equal [21]. Full country-specific 
data on the prevalence and incidence of schizophrenia are 
shown in Table 1. No published data for Slovakia and Hun-
gary were available. 
Data on the frequency of negative symptoms were lim-
ited and inconsistent. The heterogeneity of the published 
data reflects the use of different definitions and methods for 
evaluating negative symptoms. Irrespective of these limita-
tions, the published data relating to negative symptoms indi-
cated the following: 
• At least one negative symptom was present in 57.6% of 
patients with schizophrenia and in 50–90% of individuals 
experiencing their first psychotic episode [5]. 
• Persistent negative symptoms were experienced by 20–
40% of patients with their first psychotic episode [41, 42]. 
• Primary negative symptoms were observed in 10–30% of 
patients, with 17.8% of patients experiencing more than 
one type of negative symptoms [41, 42]. 
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Table 1.  Epidemiological data for seven CEE countries. 
Country and Popula-
tion in 2012 [Eurostat] 
Prevalence Incidence per 1,000 population per year  
Poland 
Population: 
38,538,447 
? 1% [30] 
? Estimated number of patients with schizophrenia: 350,000–500,000 [30, 31] 
? 0.15–0.30 per 1,000 [30] 
Slovakia 
Population: 
5,404,322 
? – ? – 
Estonia 
Population: 
1,325,217 
? 6.69 per 1,000 people 
? Highest in men aged 15–44 years and women aged over 45 [32] 
? Estimated number of people with diagnosed schizophrenia: 13,000 [33] 
? Estimated at 0.45–1.30 cases per 1,000 
[32, 34] 
Serbia 
Population: 
7,216,649 
? 5.41 per 1,000 patients  
? Estimated number of patients with schizophrenia: 31,149 [35] 
? – 
Croatia 
Population: 
4,275,984 
? 3.94–5.1 per 1,000 population [36, 37] 
? Number of diagnosed patients with schizophrenia registered in primary care: 
56,763 [38] 
? 0.21–0.27 per 1,000 [36, 37] based on 
ICD-10 criteria 
Slovenia 
Population: 
2,055,496 
? Estimated number of patients with schizophrenia: 19,000 [39] 
? 10,294–20,588 (prevalence 0.5–1.0%) [40] 
? 0.15 per 1,000 (range 0.08–0.43) [39] 
? 0.04–0.22 according to DSM-IV [40] 
? 0.05-0.23 according to ICD-10 [40] 
Hungary 
Population: 
9,931,925 
? – ? – 
– Data not identified in search 
DSM-IV=Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; ICD-10= International Classification of Diseases 10th Revision  
 
• The most frequent negative symptoms reported were so-
cial withdrawal (45.8%) and emotional withdrawal 
(39.1%) [5]. 
Mortality 
All mental illnesses are associated with an increased risk 
of premature death. A substantial number of publications 
identified here reported higher mortality in people with 
schizophrenia compared with the general population, with 
standardized mortality ratios ranging from 2.58 to 4.30 [25, 
43]. 
One reason for the excess mortality in patients with 
schizophrenia is suicide rate, which is ten times higher 
among people with mental illness than in the general popula-
tion [43]. In addition, comorbidities, such as cardiovascular 
disease, stroke, chronic lung disease and infection are in-
creased in patients with schizophrenia compared with the 
general population [16, 43]. The most frequently cited rea-
sons for elevated mortality in schizophrenia are outlined in 
Table 2 [21, 23, 25, 27, 43]. 
Clinical Practice Guidelines 
The literature search identified 11 international, impor-
tant publications that contained guidelines and recommenda-
tions for the treatment of patients with schizophrenia. These 
are summarized in Table 3. 
Table 2.  Reasons for elevated mortality in schizophrenia. 
Reason Examples 
Direct effect of mental illness or 
treatment-related adverse effect 
Worsening of metabolic profile 
leading to increased risk of car-
diovascular disease  
Effect of mental illness on life-
style and environment/patients’ 
negative attitude towards their 
physical health 
Increased probability of smoking, 
alcohol use, drug use, physical 
inactivity, and poor diet – leading 
to increased risk of cardiovascular 
disease 
Natural causes of death Cardiovascular disease, stroke, 
chronic lung disease and infec-
tions 
Suicide - 
 
All the identified guidelines recommended pharmacother-
apy with either first- or second-generation antipsychotics for 
the treatment of schizophrenia. However, according to guide-
lines, pharmacotherapy does not address all aspects of schizo-
phrenia and should always be accompanied by psychosocial 
intervention. Guidelines indicate that a personalized treatment 
approach is a key to optimizing therapeutic effect and that 
givies patients a choice in treatment and encourages patients 
compliance. Recommendations suggest low doses initially 
with gradual increases to achieve an optimal 
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Table 3.  Summary of guidelines identified in the literature search. 
Source Publication year(s) 
World Federation of Societies of Biological Psychiatry [44–47] 2005, 2006, 2012, 2013 
British Association for Psychopharmacology [48] 2011 
National Institute for Health and Care Excellence [29] 2010 
The Schizophrenia Patient Outcomes Research Team [49] 2010 
American Psychiatric Association [50, 51]  2004, 2009 
Royal Australian and New Zealand College of Psychiatrists [52] 2005 
Canadian Psychiatric Association [53] 2005 
Other key guidelines, e.g. for long-acting injections and negative symptom management [6] (various) 
 
balance of efficacy and tolerability. The use of antipsychotic 
therapy and the decision to switch between them, should be 
clinically justified (for example, by poor compliance, drug 
intolerance or lack of efficacy). Use of more than one antipsy-
chotic (polytherapy) is not recommended in the guidelines, 
except for short periods, such as when switching medications. 
Second-generation antipsychotics are recommended as 
first-line therapy and as a treatment option in case of side 
effects with first-generation antipsychotics. When treating 
people with a first episode of schizophrenia, antipsychotic 
medication may be initiated at the lower end of the licensed 
dosage range. Moreover, treatment with the lowest effective 
dose is recommended throughout the course of schizophre-
nia. All available guidelines indicate clozapine for treatment-
resistant schizophrenia (defined as the patient not responding 
adequately to treatment despite the sequential use of ade-
quate doses of at least two different antipsychotic drugs, in-
cluding at least one non-clozapine second-generation antip-
sychotic). It is important to monitor patients’ physical health, 
with a particular focus on the risk of cardiovascular disease. 
Several guidelines also indicate that electroconvulsive ther-
apy should be considered for treatment of schizophrenia if 
clozapine is not effective. 
Most of the guidelines recommend that acute schizophre-
nia episodes should be treated with antipsychotic medication, 
although they note that antipsychotics are more effective at 
alleviating positive rather than negative symptoms. Both pri-
mary and secondary negative symptoms may present in the 
course of illness, and distinguishing between them is key for 
optimal treatment. Possible causes of secondary negative 
symptoms should be identified and managed as appropriate. 
The guidelines, in particular the World Federation of Societies 
of Biological Psychiatry guidelines (WFSBP), state that dif-
ferent treatments and strategies may potentially be needed for 
comorbid conditions, such as antidepressants for depression, 
anxiolytics for anxiety disorders, and antiparkinsonian agents 
or antipsychotic dose reduction for extrapyramidal symptoms. 
The WFSBP guidelines also note that first-generation antipsy-
chotics are helpful in the treatment of secondary but not pri-
mary negative symptoms. Second-generation antipsychotic 
drugs seem to be superior to first-generation drugs in the 
treatment of primary negative symptoms, although the relative 
efficacy of first- and second-generation antipsychotics for the 
treatment of secondary negative symptoms has not been estab-
lished in clinical trials [46]. 
Our literature search indicates that there is insufficient evi-
dence to support treatment recommendations regarding phar-
macotherapy for primary or persistent negative symptoms in 
schizophrenia. Nevertheless, there is a clear need to help pa-
tients experiencing negative symptoms. The 2012 WFSBP 
guidelines recommend two second-generation antipsychotic 
drugs for the treatment of primary and secondary negative 
symptoms: olanzapine and amisulpride (Table 4) [46]. 
CEE-SPECIFIC GUIDELINES  
Local-language CEE-specific schizophrenia treatment 
guidelines are listed in the Appendix. Importantly, these pub-
lications are in agreement with the non-CEE guidelines with 
respect to the treatment of schizophrenia.  
DISCUSSION 
Schizophrenia is a prevalent mental health illness and 
poses a considerable burden on patients and healthcare re-
sources worldwide. The worldwide incidence of schizophre-
nia reported in this review varies from 0.04 to 0.58 per 1,000 
population per year. However, when the diagnosis is made 
according to DSM or ICD core criteria, and corrected for 
age, mean incidence is 0.11 (range 0.07–0.17) per 1,000 
population per year [16]. Gender differences in schizophre-
nia include an earlier age of onset in men. Estimates of the 
lifetime prevalence of schizophrenia range from 0.4% to 
1.4%. The early age of onset and the chronic disease course 
may explain these relatively high figures.  
Many publications report higher mortality among indi-
viduals with mental illness compared with the general popu-
lation. Standardised mortality ratios for patients with schizo-
phrenia vary from 2.58 to 4.30. It is known that the suicide 
rate is increased among patients with schizophrenia; other 
reasons for the mortality excess include cardiovascular dis-
ease, stroke, chronic lung disease and infections [26, 43]. 
The risk of mortality in patients with schizophrenia may also 
be affected by demographic, clinical, political (pharmaco-
economic) and cultural factors [23]. Patients with schizo-
phrenia may also have limited access to and lower quality of 
healthcare services compared with the general population. 
Importantly, adherence to guideline-recommended pharma-
cotherapy is associated with reduced mortality among pa-
tients with schizophrenia [23, 27]. 
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Table 4.  WFSBP 2012 recommendations for treatment of primary and secondary negative symptoms [46]. 
Primary negative symptom Secondary negative symptom 
Antipsychotic agent 
Category of evidence Recommendations Category of evidence Recommendations 
Amisulpride A 1 A 1 
Asenapine F - B 3 
Aripiprazole C3 4 A 1 
Clozapine C3 4 A 1 
Haloperidol F - A 1 
Iloperidone F - F - 
Lurasidone F - B 3 
Olanzapine A 1 A 1 
Paliperidone F - A 1 
Quetiapine B 3 A 1 
Risperidone F - A 1 
Sertindole F - A 1/2 
Ziprasidone B 3 A 1 
Zotepine D 5 A 1 
Category of evidence: A: Full evidence from controlled studies; B: Limited positive evidence from controlled studies; C: Evidence from uncontrolled studies or case reports/expert 
opinion, C1: Uncontrolled studies; C2: Case reports; C3: Evidence is based on the opinion of experts in the field or clinical experience; D: Inconsistent results – positive randomized 
controlled trials are outweighed by an approximately equal number of negative studies; E: Negative evidence; F: Lack of evidence 
Recommendation: Grade1: Category A evidence and good risk–benefit ratio; 2: Category A evidence and moderate risk–benefit ratio; 3: Category B evidence; 4: Category C evi-
dence; 5: Category D evidence. 
 
The guidelines identified in the literature review unani-
mously state that pharmacotherapy with antipsychotic drugs is 
the cornerstone of schizophrenia treatment. However, psycho-
therapy (such as social support, psychoeducation, cognitive 
behavioural therapy, family intervention, and art therapy) may 
accompany pharmacotherapy. Guidelines recommend that use 
of more than one antipsychotic drug should be avoided, except 
when switching antipsychotic agents or if other treatments 
have failed. 
Guidelines for the treatment of negative symptoms stress 
the importance of distinguishing between primary negative 
symptoms and secondary negative symptoms. The treatment 
of secondary negative symptoms is based on identifying and 
treating the underlying causes (such as Parkinson’s syn-
drome, major depression or extrapyramidal symptoms). In 
some cases clozapine alone or in combination with antipsy-
chotics or other medication is recommended. The recently 
published WFSBP guidelines indicate that two second-
generation antipsychotic drugs – olanzapine and amisulpride 
– may be efficacious in the treatment of primary negative 
symptoms [46].  
The objective of this study was to gather data related to 
the burden of schizophrenia in seven CEE countries, with a 
particular focus on negative symptoms. Despite the extensive 
search, we were unable to find relevant data in all areas of 
interest. In particular, there was a lack of information regard-
ing socioeconomic status and mortality in patients with 
schizophrenia in many countries. Consequently, data ob-
tained from the main literature search was supplemented 
with information from non-CEE countries, such as the 
WFSBP guidelines. In addition, the data presented in this 
review are derived from many different types of publica-
tions. Epidemiological data were identified in the local lit-
erature and extracted from reviews, textbooks, health statis-
tics, national registries and local publications, which makes 
comparison between sources difficult. Furthermore, many 
countries do not have their own national guidelines. National 
guidelines and treatment recommendations for schizophrenia 
were identified in Hungary, Poland and Croatia and Estonia. 
CONCLUSION 
This comprehensive review of current literature and 
guidelines confirms that schizophrenia is a common mental 
illness that places a substantial burden on the patient and 
wider society. Guidelines recognize a role for second-
generation antipsychotics in the treatment of negative symp-
toms. However, these findings indicate that there is currently 
insufficient evidence to support treatment recommendations 
regarding pharmacotherapy for primary or persistent nega-
tive symptoms in schizophrenia. Thus, options for treatment 
of negative symptoms are limited. This literature review 
highlights the importance of developing new therapeutic 
approaches, and exploring novel therapies such as glutama-
tergic agents, which may be of great value in future treat-
ment strategies. There remains an important unmet clinical 
need in schizophrenia regarding treatment of negative symp-
toms, and improvement of overall patient outcomes.  
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APPENDIX 
Guidelines identified in local literature review 
Country Identified guidelines 
Croatia ? ?trkalj Ivezi? S, Folnegovi? ?malc V, Mimica N, 
Bajs Bjegovi? M, Makari? G, Bagari? A, et al. 
(2001). Dijagnosti?ke I Terapijske Smjernice (Algo-
ritam) Za Lije?enje Shizofrenije Preporuke 
Hrvatskog Dru?tva Za Klini?ku Psihijatriju 
Hrvatskoga Lije?ni?kog Zbora Lije?ni?ki Vjesnik : 
Glasilo Hrvatskoga Lije?ni?kog Zbora (0024-
3477)123:287-338. 
? ?trkalj-Ivezi? S; Folnegovi?-?malc V (1999). 
Terapijski algoritam shizofrenije Urednik/ci: ?trkalj-
Ivezi? S, Folnegovi?-?malc V Izdava?: Hrvatski 
Lije?ni?ki zbor, Hrvatsko dru?tvo za klin. Psihi-
jatriju, 1999. 
? Mimica N (1999). Psihofarmakologija odr?avanja 
Terapijski algoritam shizofrenije [Therapeutic algo-
rithm for schizophrenia Psychopharmacology of 
maintenance] Izvornik: Priru?nik za pra?enje semi-
nara Terapijski algoritam shizofrenije Dio CC 
?asopisa: NE Skup: Terapijski algoritam shizofrenije, 
Zagreb, Republika Hrvatska. 10:22.-23. 
Estonia ? Kleinberg A, Poolamets P, Hüva K, Tänna K, 
Jaanson P. Eesti Psühhiaatrite Selts. Skisofreenia 
ravijuhis. 2000. Published online 
http://www.kliinikum.ee/psyhhiaatriakliinik/lisad/rav
i/ps-ravi/SCH/skisofreenia_ravijuhis.htm. Accessed 
17 April 2014. 
Hungary* ? Herold R (2012). A szkizofrénia hosszú távú 
kezelése Orvosi Hetilap. 153:1007-12. 
? Fekete S, Herold R, Tényi T, Trixler M. Szki-
zofrénia szakmai protokoll, Pszichiátriai útmutató, 
2010. 
? Pszichiátriai Szakmai Kollégium. Skizofrénia szak-
mai protokoll: az Egészségügyi Minisztérium 
szakmai protokollja Útmutató. Klinikai Irányelvek 
Kézikönyve-Pszichiátria, 2008. 
? Bitter I., Jermendy Gy (2005). Antipszichotikus 
terápia és metabolikus szindróma - A Magyar Diabe-
tes Társaság Metabolikus Munkacsoportja és a 
Pszichiátriai Szakmai Kollégium konszenzus-
értekezlete Psychiatria Hungarica.20:312-5. 
? Bitter I (2004). A szkizofrénia modern gyógyszeres 
kezelése Orvosi Hetilap, 145:105-9. 
? Palik É (2002). Antipszichotikum-kezelés hatása a 
szénhidrát anyagcserére Családorvosi Fórum.9:14-6. 
? Hungarian College of Neuropsychopharmacology 
(1999). Antipszichotikumok alkalmazása Psychiatria 
Hungarica.5:584-604. 
? Antipszichotikumok Konszenzus Konferencia 
(2002): Hungarian College of Neuropsychopharma-
cology, Magyar Pszichofarmakológiai Társaság, 
Magyar Pszichiátriai Társaság Antipszichotikumok 
alkalmazása Neuropsychopharmacologia Hun-
garica.4:115-21. 
? Arató M, Bánki MCs, BartkóGy, Bitter I, Bor-
vendég J, Janka Z, et al. (1996). Antipszichotiku-
mok Konszenzus Konferencia Psychiatria Hun-
garica.6:717-20. 
Poland ? Jarema M (2012). Zalecenia w sprawie stosowania 
leków przeciwpsychotycznych II generacji [Recom-
mendations for the use of second generation antipsy-
chotics]; Farmakoterapia w psychiatrii i neurologii. 
51-7. 
? Jarema M (2008). Zalecenia w sprawie stosowania 
leków przeciwpsychotycznych II generacji. Psychia-
tria Polska. 2008;6:969-77. 
? Jarema M, Rabe-Jab?o?ska J. Psychiatria. 
Podr?cznik dla studentów medycyny; Wydawnictwo 
lekarskie PZWL, Warszawa 2011 
? Kiejna A, Landowski J et al. (2006). Standardy lec-
zenia farmakologicznego schizofrenii [Pharmacol-
ogical standards in schizophrenia treatment] Psychia-
tria Polska 40:1171-205. 
Serbia ? Ja?ovi?-Ga?i? M, Damjanovi? A, Le?i? To?evski 
D, ?uki?-Dejanovi? S, Vuki?-Drezgi? S. Terapijske 
smernice za le?enje shizofrenije [Therapeutic guide-
lines for treatment of schizophrenia]; Published by: 
Psychiatric branch of Serbian Medical Society, 
Printed by: Grafolik (not indexed by National Li-
brary of Serbia), 2008 
Slovakia ? Vavru?ová L., Ko?ínková V., Pe?e?ák J., Korcsog 
P., Jano?ka D.; Racionálna lie?ba antipsychotikami 
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